Who are Catapresan TTS 2's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Brimonidine/Timolol mixed combination, Intravenous dexmedetomidine, dexmedetomidine 1 µg/kg IV, mometasone furoate + Oxymetazoline, Escitalopram+Mirtazapine, Clonidine Oral Liquid Product.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/catapresan-tts-2.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Catapresan TTS 2 — Competitive Intelligence Brief

Catapresan TTS 2 (Catapresan TTS 2) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Central alpha-2 adrenergic agonist. Area: Cardiovascular.

marketed Central alpha-2 adrenergic agonist Alpha-2 adrenergic receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Catapresan TTS 2 (Catapresan TTS 2) — Heart Care Foundation. Clonidine reduces blood pressure by stimulating alpha-2 adrenergic receptors in the brain, decreasing sympathetic nervous system activity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Catapresan TTS 2 TARGET	Catapresan TTS 2	Heart Care Foundation	marketed	Central alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
Brimonidine/Timolol mixed combination	Brimonidine/Timolol mixed combination	Seoul National University Hospital	marketed	Alpha-2 adrenergic agonist / Beta-blocker combination	Alpha-2 adrenergic receptor; Beta-1 and Beta-2 adrenergic receptors
Intravenous dexmedetomidine	Intravenous dexmedetomidine	University of Jordan	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
dexmedetomidine 1 µg/kg IV	dexmedetomidine 1 µg/kg IV	American University of Beirut Medical Center	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
mometasone furoate + Oxymetazoline	mometasone furoate + Oxymetazoline	Guangzhou Women and Children's Medical Center	marketed	Intranasal corticosteroid + nasal decongestant combination	Glucocorticoid receptor (mometasone); alpha-2 adrenergic receptor (oxymetazoline)
Escitalopram+Mirtazapine	Escitalopram+Mirtazapine	Ministry of Health & Welfare, Korea	marketed	Antidepressant combination (SSRI + NaSSA)	Serotonin transporter (SERT), norepinephrine transporter (NET), alpha-2 adrenergic receptors, histamine H1 receptors
Clonidine Oral Liquid Product	Clonidine Oral Liquid Product	Region Örebro County	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Central alpha-2 adrenergic agonist class)

Addrenex Pharmaceuticals, Inc. · 1 drug in this class
Heart Care Foundation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Catapresan TTS 2 — Competitive Intelligence Brief. https://druglandscape.com/ci/catapresan-tts-2. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab